OXB
Total Voting Rights
Oxford, UK – 02 November 2026: OXB (LSE: OXB) (the “Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1R, the Company’s issued share capital as at the close of business on 31 October 2026 consisted of 121,459,900 ordinary shares of 50 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.
Accordingly, the total number of voting rights in OXB at the date of this notice is 121,459,900.
The above figure 121,459,900 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, OXB under the FCA's Disclosure Guidance and Transparency Rules.
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary - T: +44 (0) 1865 783 000 / E: [email protected]
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: [email protected]
Mary-Jane Elliott / Sarah Elton-Farr / Phillip Marriage
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors, the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing development and manufacturing expertise for lentiviral, AAV, adenoviral, MVA and other viral vectors. Building on its viral vector leadership, OXB also supports the development of emerging in vivo therapies through its expertise in vector engineering, manufacturing platforms, and novel envelope technologies. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE 250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.